factually
Index/Organizations/ALZ-NET

ALZ-NET

Fact-Checks

3 results
Jan 23, 2026
Most Viewed

How do amyloid PET and CSF biomarker tests influence eligibility for FDA‑approved Alzheimer’s therapies?

‑approved anti‑amyloid therapies for early symptomatic Alzheimer’s disease require evidence of brain amyloid pathology before initiation, and clinicians most commonly rely on amyloid PET imaging or ce...

Dec 5, 2025
Most Viewed

What are the costs, insurance coverage, and access issues for newly approved Alzheimer’s therapies in 2025?

New disease‑modifying monoclonal antibodies for early Alzheimer’s—lecanemab (Leqembi) and donanemab (Kisunla)—are expensive at scale (Leqembi cited at $26,500/year; Kisunla initial pricing described a...

Dec 12, 2025

Alzheimer’s treatment

Alzheimer’s treatment in 2025 is a rapidly changing field: two anti‑amyloid monoclonal antibodies (lecanemab/Leqembi and donanemab/Kisunla) have FDA approval and show plaque reduction with modest slow...